Mark Hollmer

Biography for Mark Hollmer

Mark Hollmer is a veteran life sciences journalist. Before joining FierceMarkets, he was a staff writer for "The Gray Sheet," an Elsevier Business Intelligence publication, where he wrote about medical device and diagnostics startups, and regulatory milestones for large companies in both sectors, among other topics. Previously, he spent several years as a life sciences and health care reporter at the Boston Business Journal, where he followed the biotechnology, medical devices, hospital and health insurance industries. While there, he spoke regularly about top life sciences stories during appearances on New England Cable News, and commented on the growth of the Bay State's life sciences industry as part of a special that aired on the WGBH Boston public television station. Separately, he served a stint at Brown University, promoting innovations generated by the school's life sciences researchers and medical school. Mark lives with his partner in Washington, D.C. where he enjoys the region's multiple museums, great restaurants and excellent cultural scene.

Articles by Mark Hollmer

TriVascular Technologies to target $13-$15 per share as IPO terms become clear

TriVascular Techologies is setting the terms for its planned IPO, and the California maker of stent grafts to treat abdominal aortic aneurysms aims for a fairly robust debut.

Jury partially faults J&J in another vaginal mesh trial verdict

Johnson & Johnson's Ethicon arm has been ordered to pay $1.2 million in damages in a trial alleging it produced faulty vaginal mesh that was implanted into a 64-year-old woman.

Holaira brings in $42M Series D to test COPD lung denervation treatment tool

Minnesota startup Holaira attracted $42 million in new financing that will back a formal human clinical trial for a lung denervation treatment that addresses chronic obstructive pulmonary disease.

The U.K.'s Cytox attracts $2.5M in new investment to pursue Alzheimer's biomarker work

U.K. diagnostics developer Cytox raised nearly $2.5 million in new funding to help expand work on the development of a viable Alzheimer's biomarker.

Myriad wins, and investors cheer, at CMS's move to reduce coverage cuts for BRCA tests

Myriad Genetics had warned that CMS reimbursement for its BRCA predictive cancer tests could drop by close to 50% this year. Payments are indeed declining, but the Utah diagnostics company disclosed in a recent regulatory filing that they won't drop nearly as much as previously expected.

Biotronik proceeds with MRI-safe ICD study in the U.S. as initial patients join in

A few weeks after the FDA allowed Biotronik to expand its ProMRI trial to implantable cardioverter-defibrillators, the company hasn't wasted any time moving ahead. The German cardiac device company said it performed initial ICD surgeries for the study at hospitals in Connecticut, Pennsylvania, North Carolina, Michigan, Virginia, New York and Oregon, generally involving its Iforia devices.

My sister, and life science's limits

On a cold January morning in 2013, my big sister, Gretchen, took her last, labored breath and died. She was 46. Over the course of her last month alive, I developed a growing sense of anger and desperation at how her doctors, as well as the drug and diagnostics industries, seemed to have failed her.

Cardinal Health will snatch up AccessClosure for $320M

Cardinal Health is snatching up California devicemaker AccessClosure for $320 million in cash, a deal that will give the Ohio healthcare services giant a line of cutting-edge vascular closure surgical devices.

Dental implant giant Straumann invests $30M into low-cost South Korean competitor

Straumann, the Swiss dental implant giant, is sinking $30 million into a low-priced competitor in South Korea with an option to buy a majority stake down the line.

Thoratec smacked with FDA Class I recall concerning heart pump backup controllers

A formal recall of Thoratec's backup power device used with its HeartMate pumps is now in place, and the FDA slapped a Class I status on the effort, its most serious designation, which means the issue can result in serious injury or death.